wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q47439880-6F2E7CEE-07ED-4C92-878C-AEB35D35DA6D
Q47439880-6F2E7CEE-07ED-4C92-878C-AEB35D35DA6D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47439880-6F2E7CEE-07ED-4C92-878C-AEB35D35DA6D
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
P2860
Q47439880-6F2E7CEE-07ED-4C92-878C-AEB35D35DA6D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47439880-6F2E7CEE-07ED-4C92-878C-AEB35D35DA6D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
33c52ce9cad044b3ce63910a25a86ff2a0050286
P2860
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.